How Should a Healthcare Organization Build a Medical Device Segmentation Policy in 2026?

What a Medical Device Segmentation Policy Actually Covers

A medical device segmentation policy is a formal, risk-based rule set for separating medical devices, clinical systems, users, and supporting infrastructure into controlled network zones. It defines which devices may communicate, with which destinations, under what conditions, and how those permissions are approved, tested, monitored, and removed. The policy should cover medical devices as both assets and active participants: infusion pumps, ventilators, patient monitors, imaging systems, laboratory analyzers, mobile carts, and connected sensors can all create security exposure even when they cannot run conventional endpoint software. It is not primarily an image-segmentation policy for scans, nor is it a generic promise to install firewalls. As of 24 September 2026, the central concern is operational resilience because healthcare organizations still operate substantial fleets of legacy equipment that cannot be patched or instrumented in the same way as laptops and servers.

Also worth reading: How Much Does Healthcare SaaS Cost in 2026, and Which Pricing Model Fits Your Organization? · Healthcare Compliance Software Comparison: Which Platform Is Right for a Growing Care Organization in 2026? · What should a healthcare organization check in an AI vendor BAA?

A useful policy translates technical network architecture into accountable decisions. It should state the purpose of each security zone, identify the owner of the medical device fleet, define permitted flows, and require compensating controls where a device cannot support encryption, host-based controls, or modern authentication. It must also distinguish between clinical availability, patient safety, and information confidentiality. Blocking a suspicious connection may be justified, but taking an infusion pump offline may create a greater immediate risk than allowing a constrained legacy protocol to operate for a defined period. The policy therefore needs authorized exception paths and emergency procedures rather than treating every alert as an automatic shutdown event.

Why Segmentation Matters for Connected Medical Devices

Medical devices are unusually difficult to secure because they combine long service lives, embedded software, constrained hardware, strict availability requirements, and limited visibility into application behavior. A modern workstation can be patched quickly, while a clinical device may remain in service for 10 to 20 years under vendor support or operational change-control constraints. Devices may also communicate through undocumented protocols or use certificates and credentials that are difficult to rotate. Network segmentation limits the reachable systems when one device is compromised, reducing the chance that a single compromised infusion pump can become a route into a broader hospital environment.

The need is not hypothetical. A cited 2024 HIMSS survey reported that 60% of health systems could not protect unmanaged medical devices, a figure that demonstrates why inventory and network visibility remain significant problems. Older devices are often “unmanaged” in the security sense even when clinical staff manage their availability, cleaning, and maintenance. The 2024 Medical Product Outsourcing discussion on the cybersecurity gap in legacy medical devices reflects the same mismatch between connected clinical technology and enterprise security programs. Segmentation is valuable because it can provide a measurable boundary around a device even when the device itself cannot be repaired or upgraded immediately.

Segmentation is not a complete medical-device security program. It does not remove weak passwords, insecure firmware, supply-chain weaknesses, or social engineering. Its value is containment: it can reduce lateral movement and make a security event smaller, slower, and easier to investigate. Healthcare leaders should judge it by documented exposure and tested restrictions rather than by the number of rules entered into a firewall console.

Core Policy Requirements and Risk-Based Zones

The first requirement is an inventory that identifies device type, manufacturer, model, serial number, software version, clinical location, network connections, responsible department, and expected service life. Without that context, teams may accidentally isolate a monitor from a middleware server while leaving an obsolete imaging workstation directly reachable. The policy should assign a risk tier based on factors such as internet exposure, patient connectivity, clinical criticality, patchability, remote administration, use of legacy protocols, and the sensitivity of data accessible from the device. A device that cannot be patched and communicates with a central monitoring platform deserves different treatment from a low-risk device with a defined vendor-supported update process.

A practical zone model might include a high-risk clinical device zone, a clinical services zone, a medical enterprise zone, a management zone, a building systems zone, and a separate environment for vendors or temporary test equipment. These labels are only examples; the correct design depends on actual traffic and clinical operations. The policy should specify default-deny behavior for unnecessary communication, explicit allowances for essential flows, and separate pathways for management, telemetry, clinical traffic, and bulk data. It should also state whether clinical devices may initiate connections to the internet. In many deployments, the safer default is to deny unsolicited outbound internet access while allowing narrowly defined vendor maintenance paths through a controlled intermediary.

A strong policy requires rules to be versioned, approved, tested, and assigned an expiration or review date. Temporary vendor access should not become permanent merely because a technician needs convenience. Exceptions should identify the business purpose, device, destination, duration, compensating controls, and approving authority. A request for remote support should not grant the vendor unrestricted access to a clinical subnet. Instead, access may be brokered through a monitored jump host with time-limited authorization and session recording.

Designing and Testing the Technical Controls

Segmentation should be designed from observed communication patterns rather than from assumptions about what devices “should” need. Teams can use switch port data, packet captures from designated monitoring points, device documentation, vendor interviews, and clinical workflow interviews to map dependencies. They should record which devices send telemetry, which systems receive alarms, which servers initiate software updates, and whether any equipment depends on peer-to-peer discovery. The result will rarely be a perfect dependency map, but a documented and regularly refreshed map is more useful than an unverified static diagram.

Technical implementation may involve virtual LANs, private VLANs, dedicated switches, firewall policy, host firewalls, secure web gateways, application allowlisting, identity-based access, or microsegmentation. The control must fit the environment. A patient monitor with a fixed clinical role may be better protected by a tightly restricted virtual network and monitored gateway than by an agent that the manufacturer does not support. A higher-capability device may support host-based rules, but those rules should be tested against vendor support statements and clinical workflows before broad deployment.

Testing should include baseline verification, simulated compromise, and clinical safety review. Teams can confirm that a device can reach its required monitoring service but cannot reach unrelated administration interfaces, domain controllers, or internet endpoints. They should also test what happens when a vendor account is expired, a certificate is invalid, a maintenance session is interrupted, or a clinical device is moved to another port. A ruleset that passes a network test but prevents a nurse from receiving an alarm has failed operationally, even if the firewall reports no errors.

Change control deserves special attention. Every new device model, software upgrade, Wi-Fi assignment, telehealth workflow, or integration should trigger a review of segmentation rules. Teams should deploy changes in monitoring mode first where feasible, compare proposed traffic with known requirements, and obtain sign-off from network, clinical engineering, cybersecurity, and the device owner. Quarterly reviews may be appropriate for dynamic environments, while high-risk or temporary exceptions should be reviewed monthly or at the end of their approved period.

Comparison of Segmentation Approaches

There is no single segmentation method that fits every healthcare environment. The central trade-off is between containment, compatibility, visibility, operating effort, and cost. The following comparison uses general architectural patterns rather than claiming that one vendor or technology is universally superior.

These approaches are often combined. Network segmentation can provide the outer boundary, while identity-aware gateways or microsegmentation refine access. The best choice is the one that reduces exposure without creating an unsafe maintenance burden. If a proposed control cannot be monitored, explained, and rolled back, it should not be the only control protecting a safety-critical device.

Common Mistakes and Governance Failure Modes

One common mistake is treating segmentation as an “IT network project” while excluding clinical engineering. Nurses, biomedical engineers, infection-control teams, and device vendors often know which workflows are time-sensitive and which devices have undocumented dependencies. A policy written solely by the security team may block legitimate clinical traffic, produce excessive exceptions, and encourage staff to bypass controls. Governance should therefore assign a named clinical owner for every device category and establish a rapid process for resolving urgent conflicts.

Another mistake is confusing device connectivity with device accountability. Assigning every medical device to a VLAN does not tell the organization which device is connected, whether it is authorized, or whether its configuration matches the approved baseline. Conversely, a detailed inventory does not restrict traffic. The two programs must be linked so that discovery data, ownership records, vulnerability information, and network policy refer to the same device identities. Teams should also avoid allowing service accounts shared by dozens of devices, since removing one compromised device may otherwise require changing access for many healthy systems.

A third failure is measuring activity instead of risk. “The firewall has 100 rules” is not a useful metric. Better measures include the percentage of identified medical devices with an assigned owner, the number of devices directly reachable from the internet, the number of unauthorized lateral paths found during testing, mean time to revoke temporary access, and the proportion of exceptions reviewed before expiration. A target such as reducing reachable clinical administration interfaces by 90% may be useful only if the baseline is documented; percentages without a defined denominator can create false confidence.

Finally, organizations should not deploy segmentation without a rollback plan. Devices may have hidden dependencies, vendor software may behave differently after a port change, and emergency access procedures may fail under pressure. Policies should specify who can approve an emergency rule, how long it may last, what evidence is retained, and when normal controls are restored.

Cost, Procurement, and Implementation Timing

Segmentation costs vary because the required work depends on the device estate, network age, staffing, and existing controls. A small clinic with a handful of devices may be able to implement basic isolation through existing routers and switches. A large health system with thousands of medical devices across hospitals, ambulatory sites, and legacy infrastructure may need dedicated engineering labor, monitoring systems, gateways, clinical change windows, and years of incremental remediation. A realistic planning range for an enterprise program is often tens to hundreds of thousands of dollars for initial assessment and pilot work, while multi-site deployment can reach millions. These are planning estimates, not universal prices; actual quotes depend heavily on hardware, licensing, integration, and the number of devices that require new segments or replacement.

Procurement language should specify outcomes rather than vague promises of “AI-powered security.” A supplier should demonstrate visibility into device identity, support for the institution’s protocols, logging and retention capabilities, emergency bypass procedures, interoperability with existing firewalls and identity platforms, and measurable performance under clinical load. The contract should also define who owns discovered device data, how long it is retained, how false positives are handled, and what happens if a supported control breaks a vendor-certified workflow. Free or open-source network tools can help with discovery and rule analysis, but they still require staff time, validation, and ongoing maintenance.

A practical timeline is to spend the first 4 to 6 weeks on inventory, ownership, and traffic discovery; use weeks 6 to 12 to pilot a bounded clinical area; and then review results before expanding. A 90-day pilot can establish useful baselines, but a 30-day target is usually too short for a large fleet containing legacy equipment. Leaders should measure the percentage of devices covered, critical paths verified, and exceptions closed, rather than promising that every device will be fully segmented on a fixed date.

When to Act and How to Measure Success

Immediate action is justified when medical devices have direct internet exposure, shared credentials, unsupported software, unmanaged remote-access paths, or evidence of lateral movement. A security incident involving a clinical device, a vendor finding that a device can reach a broader clinical network, or an acquisition that connects previously separate sites should trigger a time-bound review. Less urgent situations can follow a planned risk-based schedule, but delaying work indefinitely is difficult to defend when the organization cannot identify what is connected to what. A useful initial threshold is to identify and risk-rank at least 95% of active medical devices in a defined clinical area before declaring the assessment complete.

Success should be evaluated through tests and operational metrics. Teams can measure the reduction in reachable sensitive systems, the time required to isolate a device, the number of temporary rules exceeding their expiry date, and the percentage of vendor sessions that are logged and reviewed. They should also track false-positive rates, maintenance windows, clinical workflow incidents, and the time engineering staff spend validating alerts. If segmentation causes repeated emergency bypasses or staff workarounds, the design needs revision even if the original technical target was achieved.

The strongest policy is therefore not the one with the strictest rules on paper. It is the one that makes clinical dependencies explicit, reduces real attack paths, preserves safe care, and can be maintained after the initial project ends. For B2B healthcare hygiene, compliance, and safety-operations teams, that means treating network boundaries as part of a broader safety and compliance system, with evidence that can withstand audits, vendor reviews, and operational scrutiny. As of 24 September 2026, medical-device segmentation remains an active program rather than a finished configuration, particularly where older devices and unmanaged equipment remain in service.